Detalhe da pesquisa
1.
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent ß-Thalassemia.
N Engl J Med
; 382(13): 1219-1231, 2020 03 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32212518
2.
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Ann Hematol
; 102(2): 311-321, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36635381
3.
Health-related quality of life in patients with ß-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
Eur J Haematol
; 111(1): 113-124, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37095595
4.
Sotatercept, a novel transforming growth factor ß ligand trap, improves anemia in ß-thalassemia: a phase II, open-label, dose-finding study.
Haematologica
; 104(3): 477-484, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30337358
5.
Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia.
BMJ Open
; 13(3): e066683, 2023 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36948565
6.
Transmural flow modulates cell and fluid transport functions of lymphatic endothelium.
Circ Res
; 106(5): 920-31, 2010 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-20133901
7.
Luspatercept for the treatment of anaemia in non-transfusion-dependent ß-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Lancet Haematol
; 9(10): e733-e744, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36007538
8.
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.
Leukemia
; 37(11): 2314-2318, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37752285